Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

NICE Provisionally Rejects Eisai’s Breast Cancer Drug Halaven

By Pharmaceutical Processing | July 20, 2011

The National Institute for Health and Clinical Excellence released
draft guidance Wednesday, recommending against NHS reimbursement of
Eisai’s Halaven (eribulin) as a treatment for advanced breast cancer.
The company said it was “hugely disappointed” with the decision, and
would work to overturn the recommendation.

Andrew Dillon, NICE’s chief executive, noted that the main evidence
submitted by Eisai in support of the drug was based on single trial that
compared Halaven to doctor’s choice of treatment. “Although the study
indicated that [Halaven] could potentially help patients live for a
little longer, it also caused more negative side effects than the other
treatments,” Dillon remarked. The agency also indicated that if Eisai’s
agent was backed by NICE, because of its toxicity profile it would
likely only be offered as a third- or fourth-line option after treatment
with vinorelbine and Roche’s Xeloda (capecitabine).

Specifically, NICE recommended against use of Halaven as a treatment
for locally advanced or metastatic breast cancer in patients whose
disease has progressed after at least two regimens of chemotherapy for
advanced disease. The decision came despite Eisai offering to make the
agent available at a discounted price. According to the drugmaker, the
British price of the medicine was currently the lowest in the world.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE